Osteoporosis is a condition in which the bones become weak and fragile due to the loss of tissue. This condition can arise due to hormonal changes, the deficiency of calcium or vitamin. In osteoporosis, the microstructure of bones is changed due to the change in bone mass and bone density. Osteoporosis can cause severe injury or pain and requires timely treatment. Osteoporosis patients find it difficult to comply with the strict dosage schedules of drugs, hence the drug developers are focusing on the production of osteoporosis drugs with easy dosage patterns. The increasing incidences of osteoporosis, a considerable rise in the geriatric populations along with a large prevalence of sedentary lifestyles, would supplement the developments and growth in the global osteoporosis drugs market over the analysis period. The use of RANK Ligand Inhibitors to treat osteoporosis has created opportunities for new as well as existing players, to develop new drugs in the market. Factors restraining the market growth are stringent regulatory environment and the time consuming drug approval process.

The global osteoporosis market, is segmented on the basis of Drug Type, Application and Geography. The drug types considered, in this report include Parathyroid Hormone Therapy (PTH) Drugs, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators (SERMs), RANKL (Receptor activator of nuclear factor kappa-B ligand) Inhibitors and Others (Vitamin D, Calcium). Based on applications the market is classified into Primary Type 1 Osteoporosis, Primary Type 2 Osteoporosis and Secondary Osteoporosis. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA. One of the strategies adopted by major market players is product launch. For instance, recently in 2015, Eli Lilly has launched a product named teriparatide, a new drug for osteoporosis. This drug, which can be self-injected is being delivered to patients houses directly without middlemen ship of pharmacies, which has helped company to earn additional margins. The companies profiled in this report are Aegis therapeutics, Amgen, Bone medical, Chugai pharmaceutical, Eli lilly, Merck & co., Novartis pharma, Novo nordisk, Ranbaxy laboratories and Osteologix.

KEY MARKET BENEFITS:

• The report provides a quantitative analysis of the current market and estimations through 2014-2020, which would enable the stakeholders to capitalize on prevailing market opportunities
• Extensive analysis of the global Osteoporosis Drugs market by product type helps in understanding the types of equipment that are currently used along with the variants that would gain prominence in future
• Competitive intelligence highlights the business practices followed by leading market players across various geographies
• Comprehensive analysis of factors that drive and restrict the growth of the global Osteoporosis Drugs market is provided
• SWOT analysis highlights the internal environment of leading companies for effective strategy formulation
• The Osteoporosis Drugs market scenario is comprehensively analysed in accordance to the key regions

KEY MARKET SEGMENTS:

The Osteoporosis Drugs Market is segmented as below:

Osteoporosis Drugs Market By Drug Type

• Parathyroid Hormone Therapy (PTH) Drugs
• Bisphosphonates
• Calcitonin
• Selective Estrogen Receptor Modulators (SERMs)
• RANKL (Receptor activator of nuclear factor kappa-B ligand) Inhibitors
• Others (Vitamin D, Calcium)

Osteoporosis Drugs Market By Application

• Primary Type 1 Osteoporosis
• Primary Type 2 Osteoporosis
• Secondary Osteoporosis

Osteoporosis DrugsMarket By Geography

• North America
• Europe
• Asia Pacific
• LAMEA